Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B

Status Recruiting

Clinical Trial Summary

Chronic hepatitis B (CHB) is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis B every year. 3%-5% compensatory liver cirrhosis develop to decompensated cirrhosis and suffer from series symptoms such as fatigue, edema, portal hypertension, splenomegaly, hemorrhage, hepatic encephalopathy, hepatorenal syndrome and so on. Chronic hepatitis B is closely related to the imbalance of intestinal microbiota, and the intestinal microbiota of patients is significantly different from healthy people. The response of patients to hepatitis B virus can be influenced by reconstructing intestinal flora, while Intestinal microbiota transplantation(IMT) is a significant method to achieve it. In a previous study using IMT to treat HBeAg positive chronic hepatitis B patients combined with antiviral therapy, 80% of them has reached HBeAg clearance. The investigators propose a randomized trial of IMT in patients with HBV induced cirrhosis. Patients will be randomized to either control group or IMT group over a 12 months period.

Clinical Trial Description

A group of 60 patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times IMT with gastroduodenoscopy and the time interval is generally 2 weeks. Participants can keep taking their present treatment. All participants will be assessed at baseline, after 3 months, 6 months, 12 months from baseline in order to evaluate the possible changes in:

(1)Imaging changes: Color Doppler ultrasound of portal vein, CT/MRI, Fibroscan score of liver fibrosis and steatosis, Grading of varicosity under gastroscopy(GI); (2)Basic information and symptoms; (3)Biochemical indexes: Liver function, four items of liver fiber, lipid metabolism, blood routine, coagulation function, blood ammonia, inflammation, oxidative stress, urine routine; sugar metabolism indicators (blood glucose, glycosylated hemoglobin, insulin level and insulin resistance level).

(4) Changes of gut microbiota: The changes of gut microbiota will be assessed by High-throughput sequencing (16S rRNA) on baseline, 3 months, 6 months and 12 months after treatment samples to assess changes associated with IMT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03437876
Study type	Interventional
Source	Zhongshan Hospital Xiamen University
Contact	Meiya Chen
Phone	+8618950107602
Email	meiya_chen@126.com
Status	Recruiting
Phase	N/A
Start date	October 31, 2016
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05793983` - S100A8/A9 and Innate Immunity in Liver Disease
Completed	`NCT04604860` - Use of EL-FIT App to Promote Physical Activity	N/A
Recruiting	`NCT05928624` - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients	N/A
Active, not recruiting	`NCT01438970` - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function	Phase 2
Recruiting	`NCT05998330` - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease	N/A
Completed	`NCT04581369` - Cirrhosis Medical Home	N/A
Withdrawn	`NCT04244877` - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility	Phase 3
Recruiting	`NCT04588077` - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis	Phase 4
Recruiting	`NCT05538962` - Longitudinal Monitoring of Inflammation in Cirrhosis	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Completed	`NCT03850977` - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting	`NCT03736265` - Carvedilol for Prevention of Esophageal Varices Progression	N/A
Recruiting	`NCT04530760` - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting	`NCT05093218` - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.	N/A
Recruiting	`NCT05604274` - Longitudinal Monitoring of Stool Characteristics
Recruiting	`NCT04867954` - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed	`NCT04643795` - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects	Phase 1
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed	`NCT04121520` - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Not yet recruiting	`NCT04591522` - Fecal Microbiota Transplantation in Cirrhosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms